Background: Vascular risk factors (VRFs) are known to influence cerebral small vessel disease (cSVD) burden and progression. However, their specific impact on the presence and distribution of each cSVD imaging marker (white matter hyperintensity [WMH], perivascular spaces [PVSs], lacunes, and cerebral microbleeds [CMBs]) and their spatial distribution remains unclear. Methods: We conducted a retrospective analysis of 93 patients with lacunar stroke with a standardized investigational magnetic resonance imaging protocol using a 3T scanner. WMH and PVSs were segmented semi-automatically, and lacunes and CMBs were manually segmented. We assessed the univariable associations of four common VRFs (hypertension, hyperlipidemia, diabetes, and smoking) with the load of each cSVD marker. Then, we assessed the independent associations of these VRFs in multivariable regression models adjusted for age and sex. Spatial lesion patterns were explored with regional volumetric comparisons using Pearson’s coefficient analysis, which was adjusted for multiple comparisons, and by visually examining heatmap lesion distributions. Results: Hypertension was the VRF that exhibited stronger associations with the cSVD markers in the univariable analysis. In the multivariable analysis, only lacunes (p = 0.009) and PVSs in the basal ganglia (p = 0.014) and white matter (p = 0.016) were still associated with hypertension. In the regional analysis, hypertension showed a higher WMH load in deep structures and white matter, particularly in the posterior periventricular regions. In patients with hyperlipidemia, WMH was preferentially found in hippocampal regions. Conclusions: Hypertension was confirmed to be the VRF with the most impact on cSVD load, especially for lacunes and PVSs, while the lesion topography was variable for each VRF. These findings shed light on the complexity of cSVD expression in relation to factors detrimental to vascular health.
Malignant cerebral infarction (MCI) is rare but often fatal. Early identification helps guide monitoring and decompressive surgery. This study evaluated whether serum biomarkers add predictive value beyond clinical and imaging data in severe stroke patients with anterior circulation large vessel occlusion (LVO). In this prospective study, 73 acute severe LVO stroke patients underwent whole-brain CT perfusion (CTP) with rCBV-based core measurement at admission and follow-up MRI at 24 ± 12 h for infarct and edema volume assessment. Serum biomarkers (s100b, NSE, VEGF, ICAM1) were sampled a median of 20.5 h after baseline imaging. Logistic regression models predicted MCI using baseline variables (NIHSS, ASPECTS, rCBV < 30%), adding treatment data (rtPA, mTICI, NIHSS posttreatment), and adding serum biomarkers. Performance was assessed by AUC, accuracy, F1, and cross-validated R2. MCI occurred in 18/73 (24%) patients. Baseline models showed an AUC of 0.72; adding treatment improved the AUC to 0.88. Biomarkers slightly increased the AUC (0.90) but did not improve F1. Higher s100b was associated with more severe injury but did not enhance the prediction of MCI. Models with baseline imaging and treatment best explained infarct (R2 ≈ 0.27) and edema (R2 ≈ 0.58). In conclusion, admission severity, CTP, and early treatment response are the main predictors of MCI and aid early risk stratification of patients. Despite their pathophysiologic relevance, serum biomarkers do not add substantial predictive value.
Circulating biomarkers reflecting inflammation and endothelial dysfunction have been proposed as indicators of cerebral small vessel disease; however, their relevance during the hyperacute phase of ischemic stroke remains uncertain. We aimed to determine whether circulating biomarkers measured on admission differ between small ischemic stroke subtypes and whether they provide prognostic information beyond conventional predictors. We conducted a retrospective analysis of 168 patients with acute ischemic stroke treated with intravenous thrombolysis within 4.5 h of onset, classified by MRI as having recent small subcortical infarcts (RSSI; n = 84) or small cortical or cortico-subcortical infarcts (non-RSSI; n = 84). We measured admission blood levels of interleukin-1β, interleukin-6, matrix metalloproteinase-9 (MMP-9), vascular cell adhesion molecule-1 (VCAM-1), neurofilament light chain (NfL), C-reactive protein (CRP), and leukocyte ratios, and evaluated their associations with 3‑month functional outcomes using the modified Rankin Scale. Our findings showed that RSSI patients were younger (66 vs. 74 years, p < 0.001) and had smaller infarcts (0.68 vs. 2.55 mL, p < 0.001). Higher NfL (OR 2.07, p < 0.001) and VCAM‑1 levels (OR 1.84, p = 0.034) were associated with poorer outcomes. Notably, the prognostic contribution of CRP, MMP‑9, and VCAM‑1 was more pronounced in patients with RSSI. These findings suggest that circulating biomarkers may offer additional prognostic value, with patterns varying across small ischemic stroke subtypes, though their clinical utility warrants further investigation.
Delays in hospital management resulting from the failure of emergency medical services (EMS) to activate the stroke code (SC) diminish the probability of receiving acute stroke treatment, adversely affecting patient outcomes. This study aims to analyze the proportion and characteristics of patients eligible for SC not activated by EMS, within a contemporary cohort. A retrospective cohort analysis was conducted on prehospital stroke patients from the Catalan SC registry from 2016 to June 2022, who were transported by ambulance. Patients were classified according to whether EMS activated SC or not. Baseline demographic characteristics, comorbidities, clinical episode details, and treatment timelines were analyzed. Among 34,331 subjects, 28,221 (82%) were transported by EMS, with SC activation occurring in 22,968 (81%) cases. Patients for whom SC was not activated presented with lower National Institutes of Health Stroke Scale scores and longer intervals from symptom onset. Large vessel occlusions were more frequent in EMS-activated patients (24% vs. 18%). The non-EMS-activated cohort exhibited a higher prevalence of posterior circulation occlusions. Despite the absence of initial SC activation, 28% of these patients ultimately received reperfusion therapy, albeit with significant delays compared to the EMS-activated group. Most acute neurological patients who qualify for SC activation are accurately identified by EMS. However, a substantial proportion of patients are missed, leading to treatment delays. Enhancing the capacity of EMS to recognize the clinical heterogeneity of stroke presentations is essential for prompt SC activation and optimizing patient outcomes.
2 May 2025 in Journal of NeuroInterventional Surgery
Background Evidence from randomized clinical trials shows that mechanical thrombectomy (MT) enhances functional outcomes in patients with large core ischemic stroke. Objective To evaluate trends in the use of revascularization therapies, particularly MT, and their impact on functional outcomes in patients with large core ischemic stroke in routine clinical settings. Methods Observational data from the Stroke Code Registry of Catalonia (CICAT, 2016–2024) were analyzed. Patients with anterior circulation ischemic stroke and Alberta Stroke Program Early CT Score (ASPECTS) <6, whether treated with reperfusion therapies or not, were included. Statistical analyses included trend analysis and multivariable logistic regression to identify predictors of favorable outcomes (modified Rankin Scale score 0–3 at 90 days) and mortality. Results Among 599 patients, MT use increased significantly from 22% pre-2022 to 36% post-2022. This increase was associated with improved functional outcomes, with favorable outcomes rising from 29% to 43% post-2022. MT was a significant independent predictor of favorable outcomes (OR 3.4, 95% CI 2.1 to 5.5) and reduced mortality (OR 0.46, 95% CI 0.32 to 0.68). Intravenous thrombolysis also improved outcomes (OR 2.1, 95% CI 1.3 to 3.5). The benefit of MT was consistent across ASPECTS subgroups (0–2 and 3–5). Mediation analysis indicated that 88% of improvement could be attributed to increased MT use. Conclusions Increased MT use significantly improved outcomes for patients with large core ischemic stroke, particularly after 2022. Benefits were observed across subgroups, including those with very low ASPECTS. These findings support broadening MT access and suggest the need to update treatment guidelines to consider patients with large ischemic cores, aiming to optimize outcomes in routine clinical practice.
10 November 2026 in Journal of NeuroInterventional Surgery